tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

VRDN Stock Latest News

Viridian Therapeutics’ Veligrotug Shows Promising Durability and Safety in TED Treatment, Justifying Buy Rating
RatingsViridian Therapeutics’ Veligrotug Shows Promising Durability and Safety in TED Treatment, Justifying Buy Rating
27d ago
VRDN
Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating
PremiumRatings
Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating
28d ago
VRDN
Positive Outlook for Viridian Therapeutics: Buy Rating Affirmed on Promising Trial Results and Future Prospects
PremiumRatings
Positive Outlook for Viridian Therapeutics: Buy Rating Affirmed on Promising Trial Results and Future Prospects
29d ago
VRDN
Viridian Therapeutics: Promising Data and Market Position Justify Buy Rating
PremiumRatings
Viridian Therapeutics: Promising Data and Market Position Justify Buy Rating
29d ago
VRDN
Viridian Therapeutics: Buy Rating Affirmed on Promising Phase III Results and Strategic Growth Plans
PremiumRatings
Viridian Therapeutics: Buy Rating Affirmed on Promising Phase III Results and Strategic Growth Plans
29d ago
VRDN
Promising Long-Term Data and Strategic Advancements Position Viridian Therapeutics for Growth
PremiumRatingsPromising Long-Term Data and Strategic Advancements Position Viridian Therapeutics for Growth
29d ago
VRDN
Viridian Reports Positive Phase 3 Trial Results
Premium
Company Announcements
Viridian Reports Positive Phase 3 Trial Results
29d ago
8K
VRDN
Viridian Therapeutics announces long-term durability data from THRIVE trial
Premium
The Fly
Viridian Therapeutics announces long-term durability data from THRIVE trial
29d ago
VRDN
Viridian Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating
PremiumRatings
Viridian Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating
1M ago
VRDN
Viridian Therapeutics receives FDA breakthrough designation for Veligrotug
PremiumThe Fly
Viridian Therapeutics receives FDA breakthrough designation for Veligrotug
1M ago
VRDN
Viridian Therapeutics price target lowered to $19 from $22 at B. Riley
PremiumThe Fly
Viridian Therapeutics price target lowered to $19 from $22 at B. Riley
1M ago
VRDN
Viridian Therapeutics: Strategic Developments and Strong Financial Position Justify Buy Rating
PremiumRatings
Viridian Therapeutics: Strategic Developments and Strong Financial Position Justify Buy Rating
1M ago
VRDN
Viridian Therapeutics: Hold Rating Amid Limited Near-Term Catalysts and Awaited 2026 Data
PremiumRatingsViridian Therapeutics: Hold Rating Amid Limited Near-Term Catalysts and Awaited 2026 Data
1M ago
VRDN
Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMP
Premium
The Fly
Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMP
1M ago
VRDN
Viridian Therapeutics Reports Q1 2025 Progress and Financials
Premium
Company Announcements
Viridian Therapeutics Reports Q1 2025 Progress and Financials
1M ago
VRDN
Viridian Therapeutics: Strong Financials and Promising Pipeline Justify Buy Rating
PremiumRatings
Viridian Therapeutics: Strong Financials and Promising Pipeline Justify Buy Rating
1M ago
VRDN
Buy Rating for Viridian Therapeutics: Strong Pipeline and Financial Position Drive Strategic Advancements
PremiumRatings
Buy Rating for Viridian Therapeutics: Strong Pipeline and Financial Position Drive Strategic Advancements
1M ago
VRDN
Viridian Therapeutics: Promising Outlook with Strong Pipeline and Regulatory Progress
PremiumRatings
Viridian Therapeutics: Promising Outlook with Strong Pipeline and Regulatory Progress
1M ago
VRDN
Viridian Therapeutics, Inc. (VRDN) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Viridian Therapeutics, Inc. (VRDN) Q1 Earnings Cheat Sheet
1M ago
VRDN
Buy Rating for Viridian Therapeutics Driven by Promising Pipeline and Strategic Positioning in Thyroid Eye Disease Market
PremiumRatingsBuy Rating for Viridian Therapeutics Driven by Promising Pipeline and Strategic Positioning in Thyroid Eye Disease Market
2M ago
VRDN
Viridian Therapeutics Appoints Jeff Ajer to Board
Premium
Company Announcements
Viridian Therapeutics Appoints Jeff Ajer to Board
2M ago
8K
VRDN
Viridian Therapeutics appoints Ajer to its board of directors
Premium
The Fly
Viridian Therapeutics appoints Ajer to its board of directors
2M ago
BMRN
VRDN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >